Boston Scientific Corporation $BSX Stock Sold by Sumitomo Life Insurance Co.

Sumitomo Life Insurance Co. cut its holdings in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 17.7% in the 3rd quarter, Holdings Channel reports. The fund owned 146,008 shares of the medical equipment provider’s stock after selling 31,345 shares during the period. Sumitomo Life Insurance Co.’s holdings in Boston Scientific were worth $6,373,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Perigon Wealth Management LLC bought a new position in Boston Scientific during the second quarter worth $883,000. Y Intercept Hong Kong Ltd grew its position in Boston Scientific by 148.8% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock worth $47,816,000 after purchasing an additional 670,060 shares during the last quarter. Wealthfront Advisers LLC acquired a new stake in Boston Scientific in the 2nd quarter worth $3,253,000. PensionDanmark Pensionsforsikringsaktieselskab increased its holdings in shares of Boston Scientific by 9.9% during the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock worth $13,659,000 after purchasing an additional 28,961 shares during the period. Finally, Tocqueville Asset Management L.P. bought a new position in shares of Boston Scientific during the 2nd quarter worth about $38,539,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on BSX. Barclays reduced their target price on shares of Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating for the company in a research note on Friday, October 30th. Deutsche Bank set a $48.00 price target on Boston Scientific and gave the company a “buy” rating in a research note on Thursday, October 29th. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. Oppenheimer downgraded Boston Scientific from an “outperform” rating to a “market perform” rating in a research report on Thursday, October 29th. Finally, Canaccord Genuity Group decreased their price objective on Boston Scientific from $66.00 to $48.00 and set a “buy” rating on the stock in a report on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and an average price target of $61.43.

Read Our Latest Stock Report on BSX

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $41.96 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.81 and a current ratio of 1.36. The firm’s 50-day simple moving average is $43.83 and its 200-day simple moving average is $53.26. Boston Scientific Corporation has a twelve month low of $39.57 and a twelve month high of $101.91. The firm has a market cap of $60.82 billion, a P/E ratio of 17.78, a price-to-earnings-growth ratio of 1.29 and a beta of 0.60.

Boston Scientific (NYSE:BSX – Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The firm had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the prior year, the business posted $0.75 earnings per share. The company’s quarterly revenue was up 1.4% compared to the same quarter last year. As a group, research analysts expect that Boston Scientific Corporation will post 3.17 EPS for the current fiscal year.

Boston Scientific Company Profile

(Free Report)

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

Featured Articles

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.